Hyponatremia in the cancer patient.
adrenal insufficiency
cancer
hyponatremia
immunotherapy
inappropriate ADH syndrome
onconephrology
tolvaptan
urea
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
10
02
2020
revised:
28
04
2020
accepted:
11
05
2020
pubmed:
5
6
2020
medline:
22
6
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Hyponatremia is a common electrolyte disorder observed in a wide variety of malignancies and is associated with substantial morbidity and mortality. Newer cancer therapies have improved patient outcomes while contributing to new cases of hyponatremia. Patients should be monitored closely for the development of vasopressin- and non-vasopressin-mediated hyponatremia. Acute and symptomatic forms of hyponatremia require urgent intervention, and recent findings support the correction of chronic "asymptomatic" hyponatremia. Optimizing hyponatremia may reduce medical costs, and improve cancer survival likelihood and quality of life. In this article, we review the epidemiology, pathophysiology, etiology, diagnosis, and treatment of hyponatremia in the cancer patient.
Identifiants
pubmed: 32497528
pii: S0085-2538(20)30559-7
doi: 10.1016/j.kint.2020.05.015
pii:
doi:
Substances chimiques
Antidiuretic Hormone Receptor Antagonists
0
Benzazepines
0
Tolvaptan
21G72T1950
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
870-882Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.